LUNG group 2 innate lymphoid cells as a new adjuvant target to enhance intranasal vaccine efficacy against influenza

Clare M Williams; Sreeja Roy; Wei Sun; Andrea M Furuya; Danushka K Wijesundara; Yoichi Furuya

doi:10.1002/cti2.1381

LUNG group 2 innate lymphoid cells as a new adjuvant target to enhance intranasal vaccine efficacy against influenza

Clin Transl Immunology. 2022 Mar 27;11(3):e1381. doi: 10.1002/cti2.1381. eCollection 2022.

Authors

Clare M Williams¹, Sreeja Roy¹, Wei Sun¹, Andrea M Furuya², Danushka K Wijesundara³, Yoichi Furuya¹

Affiliations

¹ Department of Immunology and Microbial Disease Albany Medical College Albany NY USA.
² Pictor Limited Auckland New Zealand.
³ The School of Chemistry and Molecular Biosciences The Australian Institute for Bioengineering and Nanotechnology The University of Queensland Brisbane QLD Australia.

Abstract

Group 2 innate lymphoid cells (ILC2) are a relatively new class of innate immune cells. Lung ILC2 are early responders that secrete type 2 cytokines in response to danger 'alarmin' signals such as interleukin (IL)-33 and thymic stromal lymphopoietin. Being an early source of type 2 cytokines, ILC2 are a critical regulator of type 2 immune cells of both innate and adaptive immune responses. The immune regulatory functions of ILC2 were mostly investigated in diseases where T helper 2 inflammation predominates. However, in recent years, it has been appreciated that the role of ILC2 extends to other pathological conditions such as cancer and viral infections. In this review, we will focus on the potential role of lung ILC2 in the induction of mucosal immunity against influenza virus infection and discuss the potential utility of ILC2 as a target for mucosal vaccination.

Keywords: IL‐33; Th2; influenza; lung group 2 innate lymphoid cells; mucosal vaccination.

Publication types

Review